|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 8/04/09 Heron Therapeutics, Inc./DE 10-Q 6/30/09 5:361K RR Donnelley/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 212K
2: EX-3.1 Copy of Registrant's Certificate of Incorporation, HTML 102K
as Amended July 29, 2009
3: EX-31.1 Certification of CEO Pursuant to Rules 13A-15(F) HTML 13K
4: EX-31.2 Certification of CFO Pursuant to Rules 13A-15(F) HTML 13K
5: EX-32 Certification of CEO and CFO Pursuant to 18 U.S.C. HTML 10K
Section 1350
| Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350 |
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of A.P. Pharma, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ronald J. Prentki, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| Ronald J. Prentki, |
| President and Chief Executive Officer |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of A.P. Pharma, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John B. Whelan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| /s/ John B. Whelan |
| John B. Whelan, |
| Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/4/09 | 8-K | ||
| For Period End: | 6/30/09 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/07/24 Heron Therapeutics, Inc./DE 10-Q 3/31/24 57:5.9M Donnelley … Solutions/FA 3/12/24 Heron Therapeutics, Inc./DE 10-K 12/31/23 72:10M Donnelley … Solutions/FA 8/23/23 Heron Therapeutics, Inc./DE S-3 4:317K Donnelley … Solutions/FA 6/30/23 Heron Therapeutics, Inc./DE S-8 6/30/23 8:270K Donnelley … Solutions/FA 3/29/23 Heron Therapeutics, Inc./DE 10-K 12/31/22 73:12M Donnelley … Solutions/FA 10/07/22 Heron Therapeutics, Inc./DE S-3 5:308K Donnelley … Solutions/FA 9/09/22 Heron Therapeutics, Inc./DE S-8 9/09/22 7:197K Donnelley … Solutions/FA 2/28/22 Heron Therapeutics, Inc./DE 10-K 12/31/21 74:12M ActiveDisclosure/FA 9/14/21 Heron Therapeutics, Inc./DE S-8 9/14/21 5:277K ActiveDisclosure/FA 5/28/21 Heron Therapeutics, Inc./DE S-3ASR 5/28/21 3:252K Donnelley … Solutions/FA 2/24/21 Heron Therapeutics, Inc./DE 10-K 12/31/20 74:12M ActiveDisclosure/FA |